Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge has advised on the sale of Westcomp AB to Tången Industrikapital AB

Pursuant to the transaction, Tången acquires approximately 91 per cent of the shares in Westcomp.
October 15, 2025

Vinge has advised Stirling Square Capital Partners (“SSCP”) in connection with the sale of part of its holding in Infobric to KKR

Pursuant to the transaction, KKR has become a significant owner, while SSCP will remain the largest owner.
October 15, 2025

Vinge advises ABG Sundal Collier in connection with Conapto's issue of subsequent senior secured bonds of SEK 1 billion

Vinge has advised ABG Sundal Collier in connection with Conapto Holding AB (publ)'s issue of subsequent senior secured bonds of SEK 1 billion, and parallel written procedure to increase the bond framework to SEK 2 billion.
October 15, 2025